Solid Results for Epcoritimab for Relapsed / Refractory CLL - Dr. Arnon Kater

Epcoritamab, a bispecific antibody, shows encouraging early results in difficult-to-treat relapsed / refractory chronic lymphocytic leukemia (CLL) patients.

CLL patients who have been failed by two or more prior lines of therapy have few choices and generally poor outcomes. Bispecific antibodies are a different type of immunotherapy that engages the T cells without modifying them as CAR-T therapy does.

Dr. Arnon Kater from Amsterdam presented the results at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL2023), October 6–9, 2023 in Boston, MA.

Read the full article on CLL Society's website at: https://cllsociety.org/2024/10/solid-...
__________________________________________________________________________________________
CLL Society Website: https://cllsociety.org/
Facebook:   / cllsociety  
Twitter:   / cllsociety  
LinkedIn:   / cll-society